Title |
The Anticoagulation of Calf Thrombosis (ACT) project: study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, April 2012
|
DOI | 10.1186/1745-6215-13-31 |
Pubmed ID | |
Authors |
Daniel Horner, Kerstin Hogg, Richard Body, Michael J Nash, Kevin Mackway-Jones |
Abstract |
Half of all lower limb deep vein thrombi (DVT) in symptomatic ambulatory patients are located in the distal (calf) veins. While proximal disease warrants therapeutic anticoagulation to reduce the associated risks, distal DVT often goes untreated. However, a proportion of untreated distal disease will undoubtedly propagate or embolize. Concern also exists that untreated disease could lead to long-term post thrombotic changes. Currently, it is not possible to predict which distal thrombi will develop such complications. Whether these potential risks outweigh those associated with unrestricted anticoagulation remains unclear. The Anticoagulation of Calf Thrombosis (ACT) trial aims to compare therapeutic anticoagulation against conservative management for patients with acute symptomatic distal deep vein thrombosis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Unknown | 52 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 17% |
Professor > Associate Professor | 6 | 11% |
Student > Master | 6 | 11% |
Student > Bachelor | 5 | 9% |
Other | 5 | 9% |
Other | 13 | 25% |
Unknown | 9 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 57% |
Nursing and Health Professions | 3 | 6% |
Social Sciences | 3 | 6% |
Agricultural and Biological Sciences | 2 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Other | 4 | 8% |
Unknown | 10 | 19% |